Genfit (GNFT) AI Stock Analysis

• Market Cap: $179.33M
• Dividend Yield: N/A
• Average Volume (3M): 245.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: -45.41%
• EPS Growth: -273.69%
• Country: FR
• Employees: 180
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 50,002,895
• 10 Day Avg. Volume: 239,968
• 30 Day Avg. Volume: 245,745
• PEG Ratio: -1.12
• Price to Book (P/B): 2.57
• Price to Sales (P/S): 2.65
• P/FCF Ratio: 12.50
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 4.29
• Enterprise Value/Gross Profit: 4.61
• Enterprise Value/Ebitda: -8.33
• 1Y Price Target: $8.41
• Price Target Upside: 88.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: €4.00 ▼(-10.31% Downside)

Genfit's overall stock score reflects strong technical momentum and improved financial performance, offset by poor valuation metrics. The stock's bullish technical indicators are a significant positive, but the negative P/E ratio and lack of dividend yield weigh heavily on the valuation score.

Positive Factors

Operational Efficiency

Genfit's focus on cost management and operational efficiency has led to a return to profitability, enhancing its long-term financial stability.

Cash Flow Improvement

Improved cash flow generation indicates Genfit's ability to sustain operations and invest in R&D, supporting long-term growth prospects.

Strategic Focus

By concentrating on Euronext Paris, Genfit aims to streamline operations and enhance focus on its core business, potentially improving strategic execution.

Negative Factors

Revenue Volatility

Volatile revenue growth suggests instability in sales performance, which could challenge Genfit's ability to maintain consistent financial results.

Asset Reduction

The reduction in total assets may limit Genfit's capacity to leverage its balance sheet for future growth, impacting long-term sustainability.

Debt Levels

While balanced, the debt level requires careful management to avoid financial strain, potentially impacting Genfit's flexibility in funding operations.

Genfit Business Overview & Revenue Model

Company Description

Genfit (GNFT) is a biopharmaceutical company specializing in the development of innovative therapeutic solutions for metabolic and chronic liver diseases. Operating primarily in the biotechnology sector, Genfit focuses on advancing its proprietary platform to identify and develop new drugs targeting conditions such as non-alcoholic steatohepatitis (NASH) and other liver-related disorders. The company is committed to improving patient outcomes through its research and development efforts, with a robust pipeline aimed at addressing significant unmet medical needs.

How the Company Makes Money

Genfit generates revenue through a combination of product development, licensing agreements, and collaborations with pharmaceutical companies. Key revenue streams include milestone payments and royalties from partnered drug candidates, particularly in the context of its lead asset, Elafibranor, which is in clinical development for NASH. Additionally, the company may receive funding from grants and research contracts aimed at advancing its scientific initiatives. Strategic partnerships with larger pharmaceutical firms enhance Genfit's financial stability and allow for shared resources in research, which can lead to significant financial returns upon the successful commercialization of its products.

Genfit Financial Statement Overview

Summary

Genfit has shown significant improvement in financial performance in 2024, with a return to profitability and stronger cash flows. Effective cost management and operational efficiency are evident, but concerns remain about historical revenue volatility and asset reduction.

Income Statement

Genfit experienced a significant recovery in 2024 with a substantial increase in revenue from 2023, resulting in a return to profitability with a net profit margin of 2.25%. The gross profit margin is robust at 99.55%, indicating effective cost management. EBIT and EBITDA margins have improved significantly, reflecting enhanced operational efficiency. However, the revenue growth has been volatile over the years, indicating a lack of stability in sales performance.

Balance Sheet

The company's financial structure shows a moderate debt-to-equity ratio of 0.90, indicating a balanced use of debt and equity. Return on Equity (ROE) is modest at 2.18%, suggesting limited profitability for shareholders. The equity ratio of 45.73% indicates a healthy balance sheet with adequate equity cushion. However, the substantial decrease in total assets over recent years might pose a risk to long-term asset sustainability.

Cash Flow

Genfit's cash flow position has improved, with a strong free cash flow growth from the previous year and a solid free cash flow to net income ratio of 9.44. The operating cash flow to net income ratio of 10.09 demonstrates effective cash generation from operations. However, the past volatility in operating cash flows might indicate future cash flow uncertainties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	45.13M	67.00M	28.57M	20.20M	80.07M	765.00K
Gross Profit	42.00M	66.70M	28.22M	19.95M	79.91M	563.00K
EBITDA	-23.26M	8.35M	-22.24M	-23.60M	71.89M	-73.03M
Net Income	-38.76M	1.51M	-28.89M	-23.72M	67.26M	-101.22M
Balance Sheet
Total Assets	216.68M	151.42M	173.87M	215.54M	281.72M	198.61M
Cash, Cash Equivalents and Short-Term Investments	107.51M	81.79M	77.79M	140.55M	258.76M	171.03M
Total Debt	138.91M	62.13M	70.18M	75.28M	74.23M	185.69M
Total Liabilities	164.21M	82.20M	105.92M	121.01M	162.62M	214.78M
Stockholders Equity	52.47M	69.22M	67.95M	94.53M	119.10M	-16.16M
Cash Flow
Free Cash Flow	-4.47M	14.22M	-57.92M	-72.64M	99.38M	-97.27M
Operating Cash Flow	-3.18M	15.20M	-55.43M	-72.64M	99.92M	-96.37M
Investing Cash Flow	-3.57M	-1.04M	2.23M	-46.27M	-3.38M	-966.00K
Financing Cash Flow	52.75M	-10.57M	-5.10M	-3.79M	-8.92M	-8.26M

Genfit Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GNFT, the sentiment is Positive. The current price of 4.46 is above the 20-day moving average (MA) of 3.71, above the 50-day MA of 3.59, and above the 200-day MA of 3.53, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 64.59 is Neutral, neither overbought nor oversold. The STOCH value of 85.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:GNFT.

Genfit Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GNFT	60 Neutral	$179.33M	-4.62	-51.06%	―	-45.41%	-273.69%
ABVX	55 Neutral	€6.87B	-31.59	―	―	―	18.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DBV	50 Neutral	€470.02M	-2.76	-241.12%	―	―	3.09%
NANO	49 Neutral	€832.03M	-23.55	―	―	―	―
OSE	49 Neutral	€128.53M	-3.62	-52.76%	―	-96.92%	-175.84%
IPH	47 Neutral	€157.43M	―	-271.32%	―	-75.86%	-30.54%

Genfit Corporate Events

Genfit SA Reports Revenue Decline and Net Loss

Genfit SA is a French biopharmaceutical company focused on the discovery and development of innovative drug candidates and diagnostic solutions, primarily targeting metabolic and liver diseases with unmet medical needs. In its latest earnings report for the first half of 2025, Genfit reported a significant decrease in revenue and a net loss, attributed to various operational and financial challenges. Key financial highlights include a drop in revenue to €33.5 million from €59 million in the same period last year, alongside a net loss of €10 million compared to a net profit of €30 million previously. The company also faced increased research and development expenses, particularly related to its VS-01 product, and a substantial rise in financial charges due to the royalty financing agreement. Despite these challenges, Genfit secured a milestone payment from Ipsen for its drug Iqirvo®, approved in Italy, which contributed €26.5 million to its revenue. Looking ahead, Genfit plans to focus on its UCD program following the discontinuation of its VS-01 program due to safety concerns. The company remains committed to advancing its pipeline and exploring strategic opportunities to enhance shareholder value.